Outcomes & Translational Science Faculty

Macarius Donneyong, PhD, MPH

Associate Professor

Dr. Donneyong's passion is to improve health equity with respect to the effectiveness, safety and adherence to prescribed medications through research. His research interests include drug-drug interactions - adverse drug events precipitated by exposure to poly-pharmacy among older adults, especially racial/ethnic minorities; and medication adherence - the role of social determinants of health and patient-provider relationships in racial/ethnic disparities in medication adherence.
Other research areas: Division of Pharmacy Practice and Science, Medication Use & Outcomes
Email Directory Page
Macarius Donneyong

Milap C. Nahata, MS, PharmD

Director, Institute of Therapeutic Innovations and Outcomes (ITIO)

Dr. Nahata teaches in the pharmacotherapy and leadership courses, conducts clinical research to evaluate the effectiveness, safety, and usage of medications in the pediatric and adult populations, directs a postdoctoral pharmacotherapy research fellowship program, and serves on the committees of various national and international organizations.
Other research areas: Division of Pharmacy Practice and Science
Email Directory Page
Milap C. Nahata

Navjot Pabla, PhD

Associate Professor

Our laboratory is focused on identifying therapeutic targets for kidney diseases. Acute kidney injury and renal cell carcinoma are the two major areas of interest. Our recent work has identified several protein kinases and membrane transporters as therapeutic targets for renal disorders. We utilize high throughput screening assays and functional genomics to identify molecular targets for renal diseases, followed by validation in in vivo animal models. The overall goal of these studies is to identify new therapeutic strategies to treat acute kidney injury and renal cell carcinoma, diseases for which no effective therapies are currently available.
Other research areas: Clinical & Pre-Clinical Pharmacology, The Division of Pharmaceutics & Pharmacology
Email Directory Page
Navjot Pabla

Mitch A. Phelps, PhD

Professor

Dr. Phelps’ lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).
Other research areas: Cancer, The Division of Pharmaceutics & Pharmacology, Clinical & Pre-Clinical Pharmacology
Email Directory Page
Mitch A. Phelps

Alex Sparreboom, PhD

Professor

Dr. Sparreboom's research studies the contribution of solute carriers to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters, translates the findings to clinical trials in collaboration with scientists and oncologists, and ultimately improves the long-term outcome of patients with cancer by modulating the therapeutic window of widely-used chemotherapeutics. His research is currently focused on the development of transport modulators that could be used in conjunction with platinum-based drugs and tyrosine-kinase inhibitors, with emphasis on the development of innovative preclinical model systems.
Other research areas: Cancer, The Division of Pharmaceutics & Pharmacology, Clinical & Pre-Clinical Pharmacology
Email Directory Page
Alex Sparreboom

Yu-Jung “Jenny” Wei, PhD

Associate Professor

Dr. Wei's area of research expertise is in geriatric pharmacoepidemiology, with specific focus areas on drug safety, drug effectiveness, and quality of medication prescribing in older adults, especially those with pain, neurodegenerative diseases (e.g., Alzheimer’s disease and related dementia [ADRD]), and nursing home stays.
Other research areas: The Division of Pharmaceutics & Pharmacology, Medication Use & Outcomes
Email Directory Page
Yu-Jung “Jenny” Wei